Skip to main content

Role of Intravenous Levetiracetam in Acute Seizure Management

167kviews
Editorial27 June 2014
Role of Intravenous Levetiracetam in Acute Seizure Management

Epilepsy is a chronic medical condition that still poses a challenge in terms of treatment. There are a variety of anticonvulsants available today, but these do not prevent frequent hospital admissions and emergency room visits. Benzodiazepines, however, remain the first line treatment in acute seizure management. The approval of phenytoin, fosphenytoin, intravenous valproate and rectal diazepam has given more options to the physicians for acute management. The approval of intravenous levetiracetam has provided another option for physicians with patients who failed the other approved anticonvulsants. Intravenous levetiracetam is approved for patients 4 years and older as an alternative to oral treatment. There have been various case reports, case series and retrospective studies showing the efficacy of intravenous levetiracetam both in status epilepticus and acute seizure exacerbation. These studies reported favorable response of intravenous levetiracetam in both adults and children. Data have even shown good results in neonates and preterm children. In this volume, we have included articles from renowned researchers in the field of neurology and epilepsy who have covered the various aspects of these agents in detail including the properties, mechanism of action, pharmacology, neurobehavioral effects and the roles of these agents in special populations. These data further show that intravenous levetiracetam can be used in acute seizure management.

This book opens with a chapter by Jennifer L. DeWolfe and Jerzy P. Szaflarski1 that discusses in detail the role of intravenous levetiracetam in the critical care setting. The literature review was conducted which showed that intravenous levetiracetam is effective in terminating different types of seizures including status epilepticus, posttraumatic and tumor related seizures, seizures due to stroke and intraparenchymal hemorrhage. The pharamacokinteics of this agent in special populations including elderly, pregnant and neurocritical patients is also discussed in this chapter. The authors concluded that there is still need for larger prospective trials, but based on current data, the drug appears to be safe and better tolerated in different subgroups of seizure population. The second chapter by Wright et al2 reviewed the current literature about the pharmacology and pharmacokinetics of intravenous levetiracetam and the safety profile of this drug in adults and children. The article also showed unique mechanism of action, linear pharmacokinetics and no known drug-drug interactions with other anticonvulsants, which makes it a viable option for acute seizure management in both adults and children. The third chapter by Aceves et al3 further discusses in detail the current data regarding the safety and tolerability of intravenous levetiracetam in children and neonates in the management of status epilepticus and acute repetitive seizures. The authors also emphasize the need for a larger prospective multicenter trial to further define the roles of these anticonvulsants in this population subgroup.

Status epilepticus (SE) is a major neurological emergency that is associated with high morbidity and mortality. Status epilepticus can cause significant neuronal injury and the patients who survive status epilepticus develop long term neurological sequelae including major cognitive issues. The fourth chapter is by Laxmikant S. Deshpande and Robert J. DeLorenzo who discuss the mechanisms of levetiracetam in the control of status epilepticus and epilepsy.4 The authors in their review focused on the unique anticonvulsant properties of levetiracetam and concluded that the unconventional mechanism of action, favorable safety profile and lack of sedating effects makes it a viable candidate to be used in the management of this neurological emergency. The fifth chapter by Hae Won Shin and Robin Davis is the review of levetiracetam as a first line treatment in status epilepticus in adult patients and the need for larger prospective trials in the future.5

The sixth chapter by Fonkem et al6 and seventh chapter by Bernett et al7 focus on a special population subgroup – those with brain tumor related seizures. Fonkem et al6 in his literature review article has shown that levetiracetam is an attractive option for brain tumor related seizures because levetiracetam can increase the sensitivity of Glioblastoma tumors to the chemotherapy drug temozolomide. Levetiracetam can also be used as prophylaxis in patients with brain tumors and in patients undergoing neurological surgery. Bernett et al7 summarize the limited data available which show the potential risk of neurobehavioral side-effects with levetiracetam in brain tumor related seizure patients and the need for future research.

The next four chapters focus on traumatic brain injury and the neuroprotective properties of Levetiracetam. The eighth chapter by Shetty et al8 discusses in detail the data available about the potential mechanism of epileptogenesis and neuroprotective properties of this agent which are beneficial in treating seizures associated with neurological conditions like status epilepticus, stroke and traumatic brain injury. The ninth chapter by Kovacs et al9 discusses the blast traumatic brain injury models, neuropathology, and implications for seizure risk. In this review, the authors reviewed the pathological results which also included immunohistochemical and special staining approaches from recent preclinical explosive blast studies to better understand the mechanism by which explosions cause brain injury. This is followed by chapter by Kirmani et al10 which discusses the role of intravenous levetiracetam in severe traumatic brain injury patients. The authors concluded, based on current literature review, that intravenous levetiracetam can be considered as a viable option in acute care settings if phenytoin is unavailable or the administration is not feasible due to side-effects.

The next chapter by Benge et al11 summarizes the limited current data available about the neurobehavioral effects of levetiracetam in traumatic brain injury patients and the need for future studies.

The last chapter is an original article by Rogers et al12 in which effects of levetiracetam on the mitochondrial membrane potential of neuronal and non-neuronal cells were examined in vitro to determine if levetiracetam influences metabolic processes in these cell types. These results suggested that both neuronal and non-neuronal anticonvulsant properties of levetiracetam involve control over energy metabolism.

This book provides a comprehensive review of the role of intravenous levetiracetam in acute seizure management and emphasizes the need of larger prospective trials to further define the role of this anticonvulsant.

5,061 views

2 citations

12,148 views

71 citations

REVIEW
4 December 2013
Clinical Pharmacology and Pharmacokinetics of Levetiracetam
Chanin Clark Wright, 7 more and BATOOL F. KIRMANI

44,325 views

101 citations

Moderate to severe traumatic brain injury (TBI) is one of the leading causes of acquired epilepsy. Prophylaxis for seizures is the standard of care for individuals with moderate to severe injuries at risk for developing seizures, though relatively limited comparative data is available to guide clinicians in their choice of agents. There have however been experimental studies which demonstrate potential neuroprotective qualities of levetiracetam after TBI, and in turn there is hope that eventually such agents may improve neurobehavioral outcomes post-TBI. This mini-review summarizes the available studies and suggests areas for future studies.

15,385 views

12 citations

Traumatic brain injury (TBI) can cause seizures and the development of epilepsy. The incidence of seizures varies from 21% in patients with severe brain injuries to 50% in patients with war-related penetrating TBI. In the acute and sub-acute periods following injury, seizures can lead to increased intracranial pressure and cerebral edema, further complicating TBI management. Anticonvulsants should be used for seizure prophylaxis and treatment. Phenytoin is the most widely prescribed anticonvulsant in these patients. Intravenous levetiracetam, made available in 2006, is now being considered as an alternative to phenytoin in acute care settings. When compared with phenytoin, levetiracetam has fewer side-effects and drug-drug interactions. In the following, the role of levetiracetam in TBI care and the supporting evidence is discussed.

14,444 views

21 citations

Intravenous (IV) levetiracetam (LEV) is currently approved as an alternative or replacement therapy for patients unable to take the oral form of this antiepileptic drug (AED). The oral form has Food and Drug Administration (FDA) indications for adjunctive therapy in the treatment of partial onset epilepsy ages 1 month or more, myoclonic seizures associated with juvenile myoclonic epilepsy starting with the age of 12 and primary generalized tonic-clonic seizures in people 6 years and older. Since the initial introduction, oral and IV LEV has been evaluated in various studies conducted in the critical care setting for the treatment of status epilepticus, stroke-related seizures, seizures following subarachnoid or intracerebral hemorrhage, post-traumatic seizures, tumor-related seizures, and seizures in critically ill patients. Additionally, studies evaluating rapid infusion of IV LEV and therapeutic monitoring of serum LEV levels in different patient populations have been performed. In this review we present the current state of knowledge on LEV use in the critical care setting focusing on the IV uses and discuss future research needs.

27,777 views

28 citations

MINI REVIEW
5 August 2013
Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
Robin Davisand Hae Won Shin
With the advent of new antiepileptic drugs comes the potential for significant advances in the emergent management of status epilepticus. Traditional antiepileptic drugs possess side effect profiles that may limit their clinical utility or lead to increased patient morbidity or mortality. The relatively recent development of levetiracetam shows promise for effective control of acute status epilepticus in adults, but current objective data of its use as a first-line agent for control of status is quite limited. This paper serves to examine existing literature while considering levetiracetam as a first-line therapy in status in the adult patient population. Indeed, existing studies are narrow in their scope, however the present data do lay a substantial foundation for further investigation of levetiracetam as a primary therapy in acute status epilepticus.

33,625 views

14 citations